Lupus nephritis, a severe kidney complication of SLE, affects up to 60% of lupus patients and is a major driver of morbidity and mortality. With the lupus market projected to reach USD 11.7 billion by 2035, lupus nephritis represents a critical treatment focus, with new biologics and targeted therapies transforming outcomes.

The market was valued at USD 3,971.53 million in 2024, about USD 4,381.4 million in 2025, and is projected to reach roughly USD 11,699.42 million by 2035, growing at a CAGR of approximately 10.32%. Growth is driven by the growing prevalence of lupus, improved diagnostic capabilities, increasing awareness of autoimmune disorders, rising adoption of biologics and targeted therapies, and supportive regulatory frameworks for orphan drugs and rare diseases.

By disease type, systemic lupus erythematosus (SLE) holds the largest share (around 80.5%), reflecting its multi-organ involvement and need for systemic therapy. Cutaneous lupus erythematosus (CLE) is the fastest-growing segment, driven by dedicated dermatologic biologic development and increased recognition of skin-dominant lupus. Other subtypes, including drug-induced and neonatal lupus, also contribute, each with specific diagnostic and treatment needs.

Treatment segmentation shows corticosteroids, immunosuppressives, biologics, and other therapies, with biologics representing the fastest-growing class due to their targeted mechanisms and improved safety profiles. Diagnosis includes laboratory tests, biopsy, and advanced autoantibody panels, each playing a critical role in early detection and disease monitoring.

End users are led by hospitals (around 38.5%), which handle complex cases and infusion therapies. Specialty clinics are the fastest-growing segment, driven by rheumatology center-of-excellence growth and focused lupus care. Homecare is also emerging rapidly, fueled by subcutaneous formulation availability and patient preference for at-home self-injection.

Regionally, North America leads with over 55% of the global market, supported by advanced healthcare infrastructure, high biologic penetration, and strong reimbursement frameworks. Europe follows with around 30%, driven by biosimilar readiness and EMA pathway harmonization. Asia-Pacific holds about 12% and is growing rapidly, fueled by NRDL inclusion, insurance expansion, and rising awareness.

Key players include GSK, AstraZeneca, Aurinia Pharmaceuticals, Roche/Genentech, Bristol-Myers Squibb, Pfizer, AbbVie, Novartis, Amgen, Johnson & Johnson, and Biogen. Strategies focus on developing novel biologics, expanding indications, and forming partnerships to enhance market reach and patient access.

Read more: Lupus Market

People Also Ask

Q1. What treatments are approved for lupus nephritis?
Approved treatments include belimumab for lupus nephritis, voclosporin (calcineurin inhibitor), and mycophenolate mofetil, with multiple candidates in trials targeting complement and B-cell pathways.

Q2. How prevalent is lupus nephritis among lupus patients?
Lupus nephritis affects 30-60% of SLE patients, with higher prevalence in certain ethnic groups, and can lead to end-stage renal disease if untreated.

Tags: lupus market, lupus nephritis, kidney disease, biologics, targeted therapy, rheumatology